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Summary
STAT proteins are a family of latent cytoplasmic tran-
scription factors that are activated by tyrosine phos-
phorylation in response to a variety of cytokines, growth
factors, and hormones. Once activated, STAT pro-
teins translocate into the nucleus and help coordinate
gene transcription. One striking feature of STAT sig-
naling is its rapid and transient activation and deacti-
vation cycle, although the molecular mechanisms re-
sponsible for this remain poorly understood. Here, we
report on a nuclear protein that contains both PDZ
and LIM domains and that interacts with activated
STAT4 molecules. We show that SLIM is an ubiquitin
E3 ligase that acts on STAT proteins to cause their
proteosome-mediated degradation and enhance their
dephosphorylation. Overexpression of SLIM leads to
impaired STAT1 and STAT4 activity due to reduced
STAT protein levels, while SLIM-deficiency results in
increased STAT expression and thus enhanced IFN
production by Th1 cells. These studies suggest that
SLIM is a novel ubiquitin E3 ligase whose targets in-
clude STAT proteins.
Introduction
Signal transducers and activators of transcription (STAT)
proteins are now recognized to be critical mediators of
cytokine signaling. Generally, the STAT signaling path-
way is triggered upon the binding of cytokines to their
specific cell surface receptors. Receptor-associated ki-
nases of the Janus (JAK) family become activated and
phosphorylate specific tyrosine residues in the cyto-
plasmic portion of the cytokine receptor that then serve
as docking sites for latent cytoplasmic STAT proteins.
Upon recruitment to the cytokine receptor, the STAT
proteins themselves become phosphorylated and trans-
locate as dimers into the nucleus where they bind to
the proximal promoters of cytokine-regulated genes
and help coordinate gene transcription. STAT4 is one
of seven mammalian STAT family members and is acti-
vated following stimulation by IL-12 or IFN-α (Nguyen
et al., 2002). STAT4 is essential for IL-12-mediated dif-
ferentiation of naive Th cells into interferon-γ (IFNγ)-*Correspondence: mgrusby@hsph.harvard.edu
3 Present address: Laboratory for Host Defense, RIKEN Research
Center for Allergy and Immunology, 1-7-22, Suehiro-cho, Tsurumi-
ku, Yokohama City, Kanagawa, 230-0045, Japan.secreting T helper 1 (Th1) cells, as evidenced by the
phenotype of STAT4-deficient mice (Kaplan et al., 1996;
Thierfelder et al., 1996), and Th1 cells are critical for
mediating the immune response to bacteria, viruses
and other intracellular pathogens.
STAT signaling is tightly regulated (Haspel and Dar-
nell, 1999), and several mechanisms have been pro-
posed to account for this control (Shuai and Liu, 2003).
For example, numerous tyrosine phosphatases have
been identified that regulate the activity of various sub-
strates at different levels in the signaling cascade (Aoki
and Matsuda, 2000; Chen et al., 2003; Haque et al.,
1998; Irie-Sasaki et al., 2001; ten Hoeve et al., 2002). In
addition, the suppressor of cytokine signaling (SOCS)
and protein inhibitor of STAT (PIAS) families of proteins
have been shown to bind to and inhibit either the cyto-
kine receptor-associated Janus kinase (JAK) or acti-
vated STAT molecule, respectively. Other posttransla-
tional modifications of STAT proteins, such as arginine
methylation (Chen et al., 2004; Mowen et al., 2001) and
ubiquitination (Hanson et al., 2003; Kim and Maniatis,
1996; Wang et al., 2000; Wang et al., 2001a) have also
been suggested as important means to regulate STAT
signaling, although these mechanisms remain poorly
defined.
Ubiquitination plays a role in regulating many cellular
processes by marking proteins, including transcription
factors, for degradation through the 26S proteosome-
dependent pathway (Liu, 2004). Conjugation of ubiqui-
tin to target proteins requires three enzymes: ubiquitin-
activating enzyme (E1), ubiquitin-conjugating enzyme
(E2), and ubiquitin ligase (E3). E3 interacts with both E2
and the target protein to facilitate the transfer of ubiqui-
tin to the substrate, and thus it is the ubiquitin E3 ligase
that confers specificity to the reaction. While a number
of ubiquitin E3 ligases have been identified to date, the
ligase responsible for ubiquitination of STAT proteins
has remained elusive. Here, we identify a novel nuclear
protein, STAT-interacting LIM protein (SLIM), as a STAT
ubiquitin E3 ligase and demonstrate that ubiquitination
is an important mechanism for regulating the STAT sig-
naling pathway.
Results
SLIM Is a Nuclear Protein that Interacts
with Activated STAT4 Molecules
To further understand how the STAT signaling pathway
is regulated, we sought to identify novel molecules that
interact with and functionally affect the activity of STAT
proteins using a yeast two-hybrid screen. We constructed
a composite bait encoding the N-terminal 133 amino
acids of the murine STAT4 protein. This region is highly
conserved in all STAT family members and has been
shown to mediate the tetramerization of STAT dimers
and other important protein-protein interactions that in-
fluence STAT function (Vinkemeier et al., 1998; Xu et al.,
1996). A cDNA library prepared from a mouse Th1 cell
clone was screened, and three clones encoding pro-
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Ateins that could specifically interact with the N-terminal
STAT4 bait were isolated. One of these clones repre- I
dsents a novel protein that contains one PDZ domain at
its N terminus and one LIM domain at its C terminus f
c(Figure 1A). The cDNA encoding SLIM is 1509 bp and
contains an open reading frame of 349 amino acids p
h(Figure 1A). Northern blot analysis of murine tissues re-v
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Figure 1. SLIM Is a Nuclear PDZ-LIM Protein that Interacts with w
Activated STAT4 a
(A) Schematic diagram of the structure (top) and predicted amino o
acid sequence (bottom) of mouse SLIM. PDZ and LIM domains are f
boxed and conserved cysteine and histidine residues in the LIM Sdomain are underlined.
o(B) Northern blot analysis of SLIM expression in mouse tissues (left)
mand primary cells (right). Full-length SLIM cDNA was used as a
probe, and probes for HPRT or β-actin were used as controls. c
(C) Western blot analysis of SLIM. Cytoplasmic (C) and nuclear (N) e
extracts from CD4+ T cells, untreated or treated with IL-12 (10 ng/ml) n
for 30 min, were subjected to immunoblot (IB) with SLIM antisera. a(D) SLIM interacts with activated STAT4. 293T cells were trans-
wfected with expression plasmids for His-SLIM (WT) or frame-shift
n(FS) mutant along with STAT4 or STAT4 (Y693F). Whole-cell ex-
tracts, untreated or treated with human IFNα (1000 U/ml) for 30 min, t
were immunoprecipitated (IP) with anti-His and immunoblotted (IB) 1
with anti-STAT4. fealed that SLIM mRNA expression is highest in lung,
lthough it is also strongly expressed in spleen and thy-
us (Figure 1B). Consistent with the fact that SLIM was
solated from a cDNA library of a Th1 cell clone, SLIM
RNA expression is also high in primary CD4+ T cells
Figure 1B) although there is no difference in expression
evel between Th1 and Th2 cells (data not shown). Other
rimary haematopoietic cells such as CD8+ T cells, B
ells, macrophages and dendritic cells also express
LIM mRNA (Figure 1B). Western blot analysis using
LIM-specific polyclonal antisera revealed an approxi-
ately 38 kDa protein present in nuclear but not cyto-
lasmic extracts prepared from primary CD4+ T cells
ither before or after stimulation with IL-12 (Figure 1C).
inally, to confirm the interaction of SLIM and STAT4 in
ammalian cells, 293T cells were transiently transfected
ith expression plasmids encoding either an epitope-
agged wild-type (WT) or a frame-shift (FS) mutant SLIM
long with either a wild-type or a tyrosine mutant (Y693F)
TAT4. Transfectants were either left unstimulated or
timulated with IFNα for 30 min, and whole-cell extracts
ere prepared and subjected to coimmunoprecipita-
ion. As shown in Figure 1D, STAT4 could be coimmu-
oprecipitated with SLIM preferentially from whole-cell
xtracts of cytokine-stimulated cells. Moreover, STAT4
Y693F), which is unable to be phosphorylated but which
an translocate into the nucleus upon overexpression,
ould not be coimmunoprecipitated with SLIM. Taken to-
ether, these results suggest that SLIM is a nuclear pro-
ein that interacts with tyrosine-phosphorylated STAT
olecules that themselves have translocated into the
ucleus following activation.
LIM Inhibits STAT4- and STAT1-Mediated
ene Expression
o examine the effect of SLIM on STAT-mediated signal
ransduction, U3A cells, which lack STAT1, were tran-
iently transfected with a luciferase reporter plasmid
ontaining two copies of a high affinity STAT site along
ith expression plasmids for SLIM and STAT1 or STAT4
nd then stimulated with IFNα. Transfection of STAT1
r STAT4 leads to a robust increase in reporter activity
ollowing stimulation with IFNα, while cotransfection of
LIM markedly impairs STAT-mediated transactivation
f the reporter (Figure 2A). SLIM also impairs STAT4-
ediated transactivation in response to IL-12 in U3A
ells stably transfected with IL-12R β1 and β2 chain
xpression plasmids (Figure 2A). In contrast, SLIM has
o effect on a reporter containing the SV-40 promoter
nd enhancer (data not shown). Finally, we examined
hether SLIM can affect the expression of an endoge-
ous STAT4 target gene. 2D6 cells, a Th1-like cell line
hat secretes IFNγ in response to stimulation with IL-
2, were stably transfected with an expression plasmid
or SLIM, or vector alone as control, and clones that
xhibit high levels of SLIM expression were established.
s shown in Figure 2B, IFNγ production in response to
L-12 stimulation is markedly abolished in two indepen-
ent 2D6 clones that overexpress SLIM. These trans-
ectants produce levels of IFNγ comparable to control
ells when stimulated with phorbol myristate acetate
lus ionomycin demonstrating that these cells do not
ave a general defect in IFNγ production. These data
Regulation of STAT Signaling by SLIM
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(A) SLIM inhibits STAT-mediated transactivation. U3A cells were transfected with a (2×) IRF-1 luciferase reporter construct and expression
plasmids for STAT 1 or STAT4, with or without SLIM. Luciferase activity was measured after stimulation with human IFNα (1000 U/ml) for 5 hr
(left and right). U3A cells, which stably express the IL-12 receptor β1 and β2 chains, were transfected as indicated and stimulated with human
IL-12 (10 ng/ml) for 5 hr before luciferase activity was measured (middle).
(B) SLIM inhibits STAT4-mediated IFNγ production in response to IL-12 in Th1 cell lines. 2D6 cell clones, stably expressing Myc-SLIM (S1, S2)
or empty vector (C1, C2), were stimulated with IL-12 (12.5 ng/ml) for 72 hr (left), or PMA (50 ng/ml) plus Ionomycin (500 ng/ml) for 24 hr
(middle), at which time IFNγ production was measured by ELISA. 2D6 clones were stimulated with IL-12 for 30 min (right) and whole cell
lysates were directly immunoblotted (IB) with anti-Myc (top) or immunoprecipitated (IP) with anti-STAT4 and immunoblotted with anti-phos-
photyrosine (middle) or anti-STAT4 (bottom).
Results represent the mean ± SD of triplicate samples.suggest that SLIM is a negative regulator of STAT-medi-
ated signal transduction.
SLIM Has Ubiquitin E3 Ligase Activity
We next investigated the mechanism by which SLIM
inhibits STAT-mediated signal transduction. The LIM
domain is thought to form a Zn finger structure not un-
like that seen in related RING finger and PHD domains
(Capili et al., 2001). Proteins containing these domains
have been shown to possess ubiquitin E3 ligase activity
and are involved in protein ubiquitination. To examine
the possibility that SLIM may function as an ubiquitin
E3 ligase, purified recombinant epitope-tagged SLIM
was mixed in vitro with E1, E2 and biotinylated-ubiqui-
tin and subjected to immunoblot analysis. As shown in
Figure 3A, SLIM possess autoubiquitination activity as
evidenced by the ladder of slower migrating ubiquiti-
nated protein seen upon addition of SLIM. This ladder
of ubiquitinated material is not seen if any one compo-
nent of the in vitro ubiquitination assay is omitted, nor
when a LIM domain-deletion mutant of SLIM is used
(data not shown).
We next examined whether STAT proteins can be a
target of SLIM-mediated ubiquitination. 293T cells were
transfected with expression plasmids for SLIM, STAT1,
or STAT4 and epitope-tagged ubiquitin. Whole cell ex-
tracts were prepared and ubiquitinated proteins were
purified on Ni-NTA beads and subjected to immunoblotanalysis for STAT1 or STAT4. As shown in Figure 3B,
both STAT1 and STAT4 are ubiquitinated in vivo only
when the cells also express SLIM. In addition, purified
recombinant SLIM could mediate the in vitro ubiquitina-
tion of purified STAT4 which was immunoprecipitated
from ConA-activated thymocytes (Figure 3C). This ef-
fect of SLIM is specific to STAT proteins as SLIM ex-
pression does not lead to the ubiquitination of p53,
while MDM2, an ubiquitin E3 ligase known to act on
p53 (Li et al., 2003), has this activity (Figure 3D). Taken
together, these data suggest that SLIM is an ubiquitin
E3 ligase and that STAT proteins are a target of SLIM-
mediated ubiquitination.
SLIM Promotes Both the Degradation
and Dephosphorylation of STAT4
Ubiquitinated proteins are often degraded through a
26S proteosome-dependent pathway (Liu, 2004), and
we therefore assessed the potential for SLIM to affect
the steady-state level of STAT4 protein expression. Im-
munoblot analysis of 293T cells transfected with an ex-
pression plasmid for epitope-tagged STAT4 revealed a
marked reduction in STAT4 protein expression upon co-
transfection with an expression plasmid for SLIM (Fig-
ure 4A). There is no difference in STAT4 mRNA levels
between cells cotransfected with wild-type SLIM or a
frame shift mutant of SLIM (data not shown). Once
again, this effect of SLIM is specific to STAT4 as SLIM
Immunity
732Figure 3. SLIM Has Ubiquitin E3 Ligase Ac-
tivity
(A) In vitro autoubiquitination assay for SLIM.
Recombinant SLIM was incubated in vitro
with ubiquitin components as indicated.
Ubiquitinated SLIM was detected by immu-
noblot (IB) with avidin-HRP.
(B) SLIM promotes ubiquitination of STAT1
and STAT4 in vivo. 293T cells were trans-
fected with expression plasmids for His-
ubiquitin, STAT1, or STAT4 and SLIM (WT) or
frame shift (FS) mutant, and treated with
MG132 (20 M) for 3 hr followed by stimula-
tion with human IFNα (1000 U/ml) for 30 min.
His-tagged proteins were purified using Ni-
NTA beads and immunoblotted (IB) with anti-
STAT1 or anti-STAT4.
(C) SLIM promotes ubiquitination of STAT4
in vitro. STAT4 proteins, immunoprecipitated
with anti-STAT4 from ConA-activated thymo-
cytes, were incubated in vitro with ubiquitin
components as indicated in the absence or
presence of recombinant SLIM. Ubiquitinated
STAT4 was detected by immunoprecipitation
(IP) and immunoblot (IB) with anti-STAT4.
(D) SLIM Does Not Ubiquitinate p53. 293T cells were transfected with expression plasmids for His-ubiquitin, Flag-p53 and SLIM or MDM2.
Whole cell extracts were immunoprecipitated (IP) and immunoblotted (IB) with anti-Flag.cient animals are born at the expected Mendelian fre-STAT4 (Figure 4C). This decrease in STAT4 expression
Figure 4. SLIM Promotes Both the Degrada-
tion and Dephosphorylation of STAT4
(A) SLIM decreases the steady state level of
STAT4 protein. 293T cells were transfected
with a fixed amount of STAT4 and increasing
amounts of SLIM (WT) or frame shift (FS) mu-
tant expression plasmids. Whole cell ex-
tracts were subjected to immunoblot (IB)
with the indicated antibodies.
(B) SLIM does not induce the degradation of
p53. Expression plasmids for SLIM or MDM2
and Flag-p53 were transfected into 293T
cells and steady state levels of p53 protein
were assessed by immunoblot (IB) with anti-
Flag.
(C) SLIM impairs the tyrosine phosphoryla-
tion of STAT4 independent of the proteosome
pathway. 293T cells were transfected with
expression plasmids for Flag-STAT4 and SLIM
(WT) or frame shift (FS) mutant. Transfected
cells were incubated in the absence or presence of MG132 (40 M) for 1 hr and either left unstimulated or stimulated with IFNα (1000 U/ml)
for 1 hr. Whole cell extracts were prepared, immunoprecipitated (IB) with anti-Flag and immunoblotted (IB) with anti-phosphotyrosine or
anti-STAT4.does not induce the degradation of p53, while MDM2 i
Mdoes have this activity (Figure 4B). Whether other pro-
teins can be a target of SLIM-mediated ubiquitination r
wremains to be determined. Taken together, however,
these data suggest that SLIM-mediated ubiquitination p
Tof STAT proteins can target them for proteosome-depen-
dent degradation. t
tBecause SLIM interacts with activated STAT4 mole-
cules in the nucleus, we next examined whether SLIM a
phas any effect on the tyrosine phosphorylation of STAT4.
Western blot analysis of 293T cells cotransfected with o
expression plasmids for epitope-tagged STAT4 and
SLIM revealed a marked reduction in the expression of E
Fboth total STAT4 protein expression, similar to that
shown in Figure 4A, as well as tyrosine-phosphorylated as not evident when the transfectants were treated with
G132, an inhibitor of the proteosome-dependent deg-
adation pathway (Figure 4C). In contrast, treatment
ith MG132 has no effect on the ability of SLIM to im-
air the expression of tyrosine-phosphorylated STAT4.
hese data suggest that SLIM may regulate STAT4 ac-
ivity by two different mechanisms: SLIM can induce
he degradation of STAT4 protein through ubiquitination
nd proteosome-dependent degradation and it can im-
air the tyrosine phosphorylation of STAT4 independent
f the proteosome pathway.
ffect of SLIM Deficiency In Vitro and In Vivo
inally, to investigate the role of SLIM in vivo, we gener-
ted SLIM-deficient mice by gene targeting. SLIM-defi-
Regulation of STAT Signaling by SLIM
733Figure 5. Effect of SLIM Deficiency In Vitro and In Vivo
(A) Generation of SLIM-deficient mice. Northern blot (left) and Western blot (right) analysis of cytoplasmic (C) and nuclear (N) extracts of splenic
CD4+ T cells from wild-type (+/+) and SLIM-deficient (−/−) mice.
(B) Enhanced production of IFNγ by SLIM-deficient cells in vitro. CD4+ T cells were purified from lymph nodes of wild-type (+/+) or SLIM-
deficient (−/−) mice and stimulated in vitro with anti-CD3 plus anti-CD28 in the presence of IL-12. IFNγ production upon primary (left) and
secondary (right) stimulation was assessed by ELISA.
(C) Enhanced inflammatory response to HKLM. Wild-type (+/+) and SLIM-deficient (−/−) mice were injected with HKLM at days 0 and 5. Livers
were removed and fixed at day 10, sectioned, and stained with hematoxylin and eosin.
(D) Enhanced production of IFNγ by SLIM-deficient cells in vivo. Total spleen cells from HKLM-challenged wild-type (+/+) and SLIM-deficient
(−/−) mice were stimulated in vitro with anti-CD3 for 24 hr, and IFNγ production was assessed by ELISA.
Results represent the mean ± SD of triplicate samples.
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CFigure 6. Enhanced STAT Protein Level and Tyrosine Phosphoryla-
tion in SLIM-Deficient Cells
D(A) Thymocytes were prepared from wild-type (+/+) or SLIM-defi-
cient (−/−) mice. Whole cell extracts were prepared before and after
activation with ConA for 48 hr and immunoblotted (IB) with anti- O
STAT1, anti-STAT4 or anti-HSP90. d
(B) CD4+ T cells from wild-type (+/+) and SLIM-deficient (−/−) mice
awere activated in vitro with plate-bound anti-CD3 in the presence
tof anti-CD28, IL-2 and IL-12. After 4 days, the cells were collected,
cwashed and cultured an additional 24 hr in the absence of exoge-
nous cytokines. Following restimulation with IL-12 for the indicated f
times, whole cell lysates were prepared and immunoprecipitated d
(IP) with anti-STAT4 and immunoblotted (IB) with anti-phospho- t
STAT4 or anti-STAT4.
i
t
tquency and appear healthy and fertile. Northern and
Western blot analysis of CD4+ T cells revealed that f
gSLIM mRNA and protein, respectively, are not detected
in SLIM-deficient cells (Figure 5A). SLIM-deficient mice f
fhave normal numbers of lymphocyte subsets, including
CD4+ T cells, CD8+ T cells, B cells, macrophages, den-
fdritic cells and NK cells, as assessed by flow cytometry
(data not shown). In addition, lymph nodes from SLIM- d
mdeficient animals have normal numbers of CD62L-
expressing CD4+ T cells, and CD69, CD25, and CD44 t
tare all induced by stimulation with anti-CD3 plus anti-
CD28 to levels comparable with wild-type cells, as is m
mthe proliferative response of these cells to the same
stimuli (data not shown). t
iGiven the importance of STAT4 signaling in the differ-
entiation of IFNγ-secreting Th1 cells, we chose to ex- n
camine this response in SLIM-deficient cells. CD4+ T
cells were purified from the lymph nodes of wild-type s
tand SLIM-deficient mice and stimulated in vitro with
anti-CD3 and IL-12. As shown in Figure 5B, SLIM-defi- 2
ccient Th1 cells produce approximately 2–4 fold greater
amounts of IFNγ as measured by ELISA following either
sprimary or secondary stimulation.
We next examined the response of SLIM-deficient s
imice to in vivo challenge with heat-killed Listeria mono-
cytogenes (HKLM). Wild-type and SLIM-deficient mice m
awere injected i.p. with HKLM on days 0 and 5, and livers
were then examined histologically on day 10. Whereas m
monly small numbers of mononuclear cells are found in-
filtrating the livers of wild-type mice, livers from SLIM- feficient mice show larger and greater numbers of
ocal accumulations of these cells (Figure 5C). In addi-
ion, spleen cells from HKLM-challenged SLIM-defi-
ient mice produce significantly greater amounts of
FNγ following restimulation with anti-CD3 in vitro than
o cells from wild-type mice.
Finally, immunoblot analysis of SLIM-deficient thy-
ocytes revealed higher levels of STAT1 and STAT4
rotein expression, especially upon activation with
onA (Figure 6A) and enhanced levels of tyrosine phos-
horylation of STAT4 in CD4+ T cells in response to IL-
2 stimulation (Figure 6B) as compared to wild-type
ells, consistent with the increased IFNγ production
een from these cells following activation. STAT4 mRNA
evels were not affected in the absence of SLIM (data
ot shown). Taken together, these data suggest that
LIM regulates both the level of protein expression and
he extent of STAT activation, and thus ultimately the
mount of IFNγ produced following the activation of
D4+ T cells both in vitro and in vivo.
iscussion
ur results identify SLIM as a novel nuclear LIM-
omain protein that functions as an E3 ubiquitin ligase
nd that regulates the steady-state levels of STAT4, and
hus the IFNγ response in vivo. The LIM domain is a
onserved motif found in numerous proteins whose
unctions for the most part remain unknown. This
omain has been thought to mediate protein-protein in-
eractions (Dawid et al., 1998), and indeed many bind-
ng partners for LIM-domain proteins have been iden-
ified using this motif in yeast two-hybrid screens. In
his report, we demonstrate that a LIM domain protein
unctions as an ubiquitin E3 ligase. These findings sug-
est that LIM domain proteins may constitute a new
amily of E3 ubiquitin ligases and may help clarify the
unction of many of these proteins.
SLIM may be the first E3 ubiquitin ligase with speci-
icity toward STAT proteins to be identified. Our results
emonstrate that STAT1 and STAT4 are targets of SLIM-
ediated ubiquitination, both in vitro and in vivo, al-
hough further analysis will be required to determine
he fine specificity of SLIM activity on other STAT family
embers. While our results demonstrate that SLIM can
ediate the polyubiquitination of STAT proteins and
arget them for proteosome-dependent degradation, it
s tempting to speculate that SLIM may also act to mo-
oubiquitinate STAT proteins under certain physiologi-
al conditions. Monoubiquitination of proteins has been
hown to have multiple effects (Hicke, 2001), which in
he case of p53 results in its nuclear export (Li et al.,
003), and thus SLIM may also regulate STAT activity by
ontrolling the subcellular localization of STAT proteins.
We have also shown that SLIM can impair the tyro-
ine phosphorylation of STAT4, independent of proteo-
ome-dependent degradation. While SLIM does not
tself have a putative protein tyrosine phosphatase do-
ain, there are two possibilities as to how SLIM may
ccomplish this. First, SLIM may act as an adaptor
olecule, perhaps through either its LIM or PDZ do-
ains, to recruit a nuclear tyrosine phosphatase, thus
acilitating the dephosphorylation of STAT proteins.
Regulation of STAT Signaling by SLIM
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TAK1, an ubiquitin-dependent kinase complex that
binds to and activates IκB kinase (Wang et al., 2001b).
Alternatively, the ubiquitination of the STAT protein
itself may be necessary for its dephosphorylation, per-
haps by inducing a conformational change that would
allow access by a protein tyrosine phosphatase. Again,
this would not be unlike that recently reported for Itch,
an ubiquitin E3 ligase that ubiquitinates Smad2 and, in
this case, enhances Smad2 phosphorylation indepen-
dent of changes in Smad2 protein levels (Bai et al.,
2004).
Taken together, our observations suggest that ubiqui-
tination is an important mechanism for negatively regu-
lating the STAT signaling pathway, and our data from
SLIM-deficient mice suggest that this ubiquitin E3 li-
gase controls the extent of STAT-mediated Th1 cell dif-
ferentiation and subsequent IFNγ production following
an inflammatory response in vivo. As a number of
studies have shown that STAT1 and STAT4 function is
critical for the development of autoimmune and inflam-
matory disorders, these observations suggest that
SLIM may be an attractive target for manipulating cy-
tokine responses in the treatment of these diseases.
Experimental Procedures
Yeast Two-Hybrid Screening
The N-terminal region of mouse STAT4 (amino acids 1–133) was
subcloned in-frame into pEG202 (Clontech) to generate the yeast
two-hybrid bait construct. Yeast strain EGY48 was sequentially
transformed with bait plasmid, pSH17 reporter plasmid (Clontech)
and cDNA library in pJG4-5 (Clontech) and constructed from a
mouse Th1 cell clone stimulated with anti-CD3 for 5 hr. Positive
colonies were selected on drop out and X-gal plates, and cDNA
from these colonies were retrieved and sequenced.
Expression Vectors, Recombinant Protein, and Antibodies
Flag-STAT4 was generated in pCDNA3 (Invitrogen). His- and-Myc-
SLIM were generated in pCDNA-His (Invitrogen) and pCMV-Myc
(Clontech), respectively. (2×) IRF-1 luciferase reporter plasmid was
a gift from T. Hoey. Flag-p53 and MDM2 were gifts from Z. Yuan.
For recombinant SLIM, His-SLIM was expressed in E. coli and sub-
sequently purified on a Nickel column. To generate SLIM antisera,
a GST-SLIM fusion protein was expressed in E. coli and immunized
into rabbits. Anti-Stat4 (C-20; Santa Cruz), Omni-probe (M-21; Santa
Cruz), anti-c-Myc (9E10; Santa Cruz), anti-HSP90 (H-114; Santa
Cruz) and anti-Flag (M2; Sigma) were from the indicated sources.
Cells, Transfections, and Reporter Assays
293T cells were maintained in DMEM (GibcoBRL). U3A cells were
a gift from T. Hoey and maintained in DMEM. 2D6 cells were a gift
from T. Hoey and grown in RPMI (GibcoBRL) supplemented with
15% FCS and 10% T-stim (BD Bioscience) in the presence of 250
pg/ml of IL-12. All transient transfections were carried out using
Effectene (Qiagen). To assess the effect of SLIM on steady-state
levels of STAT4 protein, 293T cells were transfected with STAT4
(0.1g) along with increasing amounts of Myc-SLIM and treated
with IFNα for 30 min. For p53 experiments, 293T cells were trans-
fected with p53 (0.1g) along with SLIM or MDM2 (1.2 g). Lucifer-
ase assays were carried out per the manufacture’s protocol (Pro-
mega). To generate stable transformants of 2D6 cells, cells were
transfected with pCMVMyc-SLIM or empty vector along with
pCDNA3 by electroporation and selected in the presence of G418
(1mg/ml) for 14 days. Northern and Western blotting were used to
identify clones that express high levels of SLIM.
Western Blot Analysis and Immunoprecipitation
Whole cells extracts were prepared by lysing cells in 250 mM NaCl,
50 mM Tris (pH 8.0), 0.5% NP-40 and protease inhibitors. Cytoplas-mic and nuclear extracts were prepared using hypotonic (20 mM
HEPES [pH 8.0], 10 mM KCl, 1 mM MgCl, 0.1% Triton X-100, 20%
glycerol) and hypertonic buffers (20 mM HEPES [pH 8.0], 1 mM
EDTA, 20% glycerol, 0.1% Triton X-100, 400 mM NaCl) as de-
scribed (Haspel and Darnell, 1999). Extracts were subjected to
SDS-PAGE and immunoblot analysis with antibodies as indicated.
For immunoprecipitation, extracts were incubated with the indi-
cated antibodies plus protein A/G-beads (Santa Cruz), washed four
times and subjected to SDS-PAGE.
Ubiquitination Assays
For in vitro autoubiquitination, recombinant SLIM was incubated
for 3 hr with biotin-ubiquitin, E1 (Boston Biochem) and UbcH8 in
ubiquitination buffer (50 mM Tris [pH 8.0], 50 mM NaCl, 1 mM ATP
and 1 mM DTT) and subjected to Western blot with avidin-HRP. For
in vitro ubiquitination assay of STAT4, STAT4, which was immuno-
precipitated from ConA-activated thymocytes, was incubated with
biotin-ubiquitin, E1 and UbcH5a (Boston Biochem) in the absence
or presence of recombinant SLIM, and then immunoblotted with
anti-STAT4. For in vivo ubiquitination assay of STAT4, 293T cells
were transfected with STAT4 and Myc-SLIM and treated with MG132
and IFNα. His-tagged proteins were purified as previously de-
scribed (Campanero and Flemington, 1997) and subjected to im-
munoblot with anti-STAT4. For in vivo ubiquitination assay of p53,
293T cells were transfected with p53 along with Myc-SLIM or
MDM2. Whole cell extracts were prepared with RIPA buffer contain-
ing 10 mM N-ethylmaleimide and subjected to immunoprecipitation
and immunoblot with anti-Flag.
Generation of SLIM-Deficient Mice
Murine SLIM genomic DNA was isolated from a C57BL/6 genomic
library. The neomycin phosphotransferase gene lacking a polyA
signal, derived from pMC1 Neo (Stratagene), was inserted into
exon 2 to construct the targeting vector. G418-resistant colonies
were screened by Southern blotting to identify homologous recom-
binants. The generation of chimeras and mutant mice was essen-
tially as described (Kasaian et al., 2002). All mice used were be-
tween 4 and 6 weeks of age.
In Vitro Th1 Cell Differentiation
CD4+ T cells were MACS-purified from lymph nodes and spleen,
and cultured with anti-CD3 (0.1 g/ml), anti-CD28 (1.0 g/ml), IL-2
(50 U/ml), and IL-12 (10 ng/ml) for 3 days for primary stimulation,
or for 5 days and then restimulated with anti-CD3 (0.1 g/ml) for
24 hr for secondary stimulation. IFNγ production was measured by
ELISA. Total spleen cells were cultured in the presence of heat-
killed Listeria monocytogenes for 4 days. Cells were then restimu-
lated with anti-CD3 for 24 hr and IFNγ production was assessed
by ELISA.
In Vivo Challenge With HKLM
Listeria monocytogenes (ATCC19111) were cultured in Brain Heart
Infusion media for 18 hr and subsequently incubated at 60 oC for
4 hr to make HKLM. Mice were injected i.p. with 1 × 109 cfu HKLM
on days 0 and 5. On day 10, livers were removed and fixed in
Bouin’s fixative solution, sectioned at 6 m, and stained with he-
matoxylin and eosin. Total spleen cells were prepared on the same
day and stimulated in vitro with anti-CD3 for 24 hr and IFNγ pro-
duction was assessed by ELISA.
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